Sort
40,608 grants matching “prostate cancer”
Molecular mechanisms of prostate cancer initiation
$1,336,237Michael M. Shen · Columbia University Health Sciences · P01 · FY2011 · CA
Mechanisms of pathogenesis in patient derived organoid models of prostate cancer
$1,336,035Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
BLOOD-BASED EPIGENOMIC CORRELATES OF AGGRESSIVE PROSTATE CANCER PHENOTYPES.
$1,335,000Dana-Farber Cancer Institute, Inc. · · FY2021 · Defense Health Agency
CANCER CENTER SUPPORT GRANT-P30
$1,334,400University Of California Davis · P30 · FY2004 · CA
Comprhensive Center of Excellence in Health Disparities
$1,333,813Timothy R Rebbeck · University Of Pennsylvania · P60 · FY2014 · MD
Somatic Mutations and Their Etiological Determinants for Breast Cancer in African American Women
$1,333,797Song Yao · Roswell Park Cancer Institute Corp · R01 · FY2019 · CA
Mechanisms of Normal Tissue Toxicity From Irradiation
$1,333,179Deborah Citrin · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3
$1,331,791David John Hunter · Brigham And Women'S Hospital · U01 · FY2007 · CA
Molecular mechanisms of prostate cancer initiation
$1,331,536Michael M. Shen · Columbia University Health Sciences · P01 · FY2012 · CA
Translational Applications of mda-7/IL-24 in Cancer
$1,329,682Paul B Fisher · Virginia Commonwealth University · P01 · FY2008 · CA
Molecular Imaging of Cancer and Its Response to Therapy
$1,328,882Kenneth A. Krohn · University Of Washington · P01 · FY2014 · CA
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities ( 1 of 3)
$1,328,312Samuel E. Adunyah · Meharry Medical College · U54 · FY2012 · CA
PROTEASES IN CANCER--BIOLOGY AND DRUG DEVELOPMENT
$1,328,283University Of California San Francisco · P01 · FY2001 · CA
TARGETING SERINE AND 1-CARBON METABOLISM FOR THE TREATMENT OF RB-DEFICIENT AGGRESSIVE-VARIANT PROSTATE CANCER
$1,327,793The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2025 · Defense Health Agency
PROSTATE CANCER CLINICAL TRIALS CONSORTIUM: JOHNS HOPKINS KIMMEL CANCER CENTER SITE
$1,327,702The Johns Hopkins University · · FY2017 · Department of the Army
DEVELOPING A CELL-FREE METHYLATED DNA-BASED BIOMARKER TO DETECT NEUROENDOCRINE PROSTATE CANCER
$1,327,500Emory University · · FY2020 · Defense Health Agency
INTEGRATIVE DISSECTION OF GERMLINE GENOMIC FEATURES DRIVING CANCER RISK, DISEASE PROGRESSION, AND RESPONSE TO THERAPY IN PROSTATE CANCER
$1,327,499Dana-Farber Cancer Institute, Inc. · · FY2021 · Defense Health Agency
DEVELOPING STRATEGIES TO OVERCOME PROSTATE STROMAL- DERIVED NRG1-MEDIATED RESISTANCE TO AR BLOCKADE IN HIGH-RISK LOCALLY ADVANCED PROSTATE CANCER.
$1,327,473Sloan-Kettering Institute For Cancer Research · · FY2021 · Department of the Army
Comprhensive Center of Excellence in Health Disparities
$1,327,473John H Holmes · University Of Pennsylvania · P60 · FY2015 · MD
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
$1,327,312University Of Colorado Denver · N01 · FY2009 · CA
1/2 Howard - Hopkins Comprehensive Alliance in Cancer Research, Education, and Equity (H2CAREE)
$1,326,910Carla D Williams · Howard University · U54 · FY2024 · CA
Mechanisms of molecular machines that regulate the neuronal cytoskeleton
$1,325,057Antonina Roll-Mecak · National Institute Of Neurological Disorders And Stroke · ZIA · FY2011 · NS
Deep South CanCORS Colorectal and Lung Cancer PDCR Site
$1,325,014University Of Alabama At Birmingham · U01 · FY2003 · CA
Animal Model and Genotyping Core Support Facility
$1,324,639Wendy Du Bois De Vroylande · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
Genomic Diversity of Prostate Cancer Across the African Diaspora
$1,324,467Timothy R Rebbeck · Dana-Farber Cancer Inst · R01 · FY2022 · CA